XT
ELVN icon

XTX Topco’s Enliven Therapeutics ELVN Stock Holding History

XTX Topco’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$505K Sell
9,957
-28,366
-74% -$1.2M 0.01% 2441
2026
Q1 		$1.5M Sell
38,323
-22,379
-37% -$620K 0.03% 1080
2025
Q4 		$935K Buy
60,702
+50,101
+473% +$998K 0.02% 1070
2025
Q3 		$0 Sell
10,601
-761
-7% -$15.3K ﹤0.01% 2736
2025
Q2 		$228K Sell
11,362
-10,487
-48% -$199K 0.01% 1620
2025
Q1 		$430K Buy
+21,849
New +$470K 0.02% 1134

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

XTX Topco's ELVN Position: Q2 2026 in Review

XTX Topco reduced its Enliven Therapeutics (ELVN) stake by 74% in Q2 2026, selling an estimated $1.2M and leaving 9,957 shares worth $505K. The position accounts for 0.01% of the portfolio, ranked #2441.

XTX Topco first reported a position in ELVN in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.5M in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • XTX Topco held 9,957 shares of Enliven Therapeutics worth $505K as of Q2 2026.
  • XTX Topco sold 28,366 Enliven Therapeutics shares in Q2 2026, an estimated $1.2M.
  • Enliven Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2441 holding.
  • XTX Topco first reported a position in Enliven Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • XTX Topco's Enliven Therapeutics position peaked at $1.5M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.